Abstract
Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Current Neuropharmacology
Title:Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models
Volume: 10 Issue: 3
Author(s): Akiyoshi Saitoh and Mitsuhiko Yamada
Affiliation:
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Abstract: Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Export Options
About this article
Cite this article as:
Saitoh Akiyoshi and Yamada Mitsuhiko, Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217314
DOI https://dx.doi.org/10.2174/157015912803217314 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Cold Case of Metabotropic Glutamate Receptor 6: Unjust Detention in the Retina?
Current Neuropharmacology Human Eosinophils - Potential Pharmacological Model Applied in Human Histamine H<sub>4</sub> Receptor Research
Current Medicinal Chemistry Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy The <i>locus</i> of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms
CNS & Neurological Disorders - Drug Targets Vascular Endothelial Growth Factor in Central Nervous System Injuries – A Vascular Growth Factor Getting Nervous?
Current Neurovascular Research Interpersonal-Psychological Precursors to Suicidal Behavior: A Theory of Attempted and Completed Suicide
Current Psychiatry Reviews Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?
Current Cardiology Reviews NMDA Pathology and Treatment of Schizophrenia
Current Pharmaceutical Design Pharmacological Properties of Novel Cyclic Pentapeptides with µ-opioid Receptor Agonist Activity
Medicinal Chemistry Cyanopeptides: A New and Nearly Inexhaustible Natural Resource for the Design and Structure-Activity Relationship Studies of New Inhibitors of Trypsin-like Serine Proteases
Current Enzyme Inhibition Applications of Chemical Shift Imaging for AD
Current Medical Imaging Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes
Current Neurovascular Research Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Searching Drug-Like Anti-cancer Compound(s) Based on G-Quadruplex Ligands
Current Pharmaceutical Design Gastrodia Elata Bl Attenuates Methamphetamine-Induced Dopaminergic Toxicity Via Inhibiting Oxidative Burdens
Current Neuropharmacology Lipid Rafts Mediate Amyloid-Induced Calcium Dyshomeostasis and Oxidative Stress in Alzheimer’s Disease
Current Alzheimer Research Environmental Tobacco Smoke Exposure and Airway Hyperresponsiveness
Inflammation & Allergy - Drug Targets (Discontinued) Methods for Evaluating Sensory, Affective and Cognitive Disorders in Neuropathic Rodents
Current Neuropharmacology